Oruka Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

ORKA$109.50+4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statement of Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except share data)

Series A Convertible Preferred Stock · Series A Non-Voting Convertible Preferred Stock · Series B Non-Voting Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated · Total Stockholders’
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balances as of February 6, 2024 (inception)	—	$—	—	$—	—	$—	3,197,975	$3	$(2)	$—	$—	$1
Issuance of common stock	—	—	—	—	—	—	2,207,553	2	(2)	—	—	—
Issuance of Series A convertible preferred stock, net of issuance costs of $69	20,000,000	2,931	—	—	—	—	—	—	—	—	—	—
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization	(20,000,000)	(2,931)	—	—	137,138	2,931	—	—	—	—	—	2,931
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization	—	—	—	—	—	—	2,722,207	3	26,445	—	—	26,448
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing	—	—	—	—	—	—	20,061,932	20	248,437	—	—	248,457
Issuance costs of Pre-Closing Financing and reverse recapitalization	—	—	—	—	—	—	—	—	(20,504)	—	—	(20,504)
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization	—	—	—	—	—	—	1,208,883	1	4,999	—	—	5,000
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the 2024 PIPE Financing	—	—	2,439	56,097	—	—	5,600,000	6	144,433	—	—	144,439
Issuance costs of 2024 PIPE Financing	—	—	—	(3,263)	—	—	—	—	(8,592)	—	—	(8,592)
Conversion of Series A non-voting convertible preferred stock to common stock	—	—	(2,439)	(52,834)	—	—	2,439,000	2	52,832	—	—	52,834
Issuance of common stock under employee stock purchase plan	—	—	—	—	—	—	2,960	—	53	—	—	53
Reclassification of the Paruka warrant from liability to equity	—	—	—	—	—	—	—	—	10,357	—	—	10,357
Stock-based compensation expense	—	—	—	—	—	—	—	—	4,562	—	—	4,562
Unrealized losses on marketable securities	—	—	—	—	—	—	—	—	—	(41)	—	(41)
Net loss	—	—	—	—	—	—	—	—	—	—	(83,724)	(83,724)
Balances as of December 31, 2024	—	$—	—	$—	137,138	$2,931	37,440,510	$37	$463,018	$(41)	$(83,724)	$382,221
Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing	—	—	—	—	—	—	10,933,405	11	179,989	—	—	180,000
Issuance cost of the 2025 PIPE Financing	—	—	—	—	—	—	—	—	(10,356)	—	—	(10,356)
Issuance of common stock upon exercise of pre-funded warrants	—	—	—	—	—	—	325,000	1	(1)	—	—	—
Issuance of common stock upon exercise of stock options and employee warrants	—	—	—	—	—	—	36,022	—	294	—	—	294
Issuance of common stock under employee stock purchase plan	—	—	—	—	—	—	35,316	—	377	—	—	377
Cancellation of restricted stock awards	—	—	—	—	—	—	(47,944)	—	—	—	—	—
Reclassification of the Paruka warrant from liability to equity	—	—	—	—	—	—	—	—	10,065	—	—	10,065
Stock-based compensation expense	—	—	—	—	—	—	—	—	14,175	—	—	14,175
Unrealized gains on marketable securities	—	—	—	—	—	—	—	—	—	587	—	587
Net loss	—	—	—	—	—	—	—	—	—	—	(105,433)	(105,433)
Balances as of December 31, 2025	—	$—	—	$—	137,138	$2,931	48,722,309	$49	$657,561	$546	$(189,157)	$471,930

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.